Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363613 | 1.00 | CYP2C9 (0.43) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL2844773 | 0.93 | CYP19A1 (0.37) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2837668 | 0.92 | CYP3A4 (0.41) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C | |
| SCHEMBL1919537 | 0.90 | ANO1 (0.43) | — | |
| SCHEMBL2835706 | 0.90 | CYP3A4 (0.36) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL1918337 | 0.90 | ATM (0.40) | — | |
| SCHEMBL1919350 | 0.90 | KDM4E (0.39) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2841611 | 0.89 | CYP2C9 (0.46) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2837475 | 0.89 | CYP3A4 (0.42) | CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL2837666 | 0.89 | CYP3A4 (0.40) | CYP2C9CYP3A4CYP2C19KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-10-16 | — | — | US | disclosed |
| US-12239629-B2 | Methods for the prophylaxis and treatment of COVID and COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4032897-B1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | GILEAD PHARMASSET LLC (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-2604620-B9 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-2604620-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20230277566-A1 | BROAD SPECTRUM ANTIVIRAL AND METHODS OF USE | THE BURLINGTON HC RES GROUP INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4138906-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | Tran, Lloyd Hung Loi (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-4032897-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Gilead Pharmasset LLC (US) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | CYP2C9 100/4885CYP3A4 422/4885CYP2C19 29/4885 |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | CYP2C9 100/4885CYP3A4 422/4885CYP2C19 29/4885 |
| US-12239629-B2 | Methods for the prophylaxis and treatment of COVID and COVID-19 | ACE, ACE2, LPO | CYP2C9 100/4885CYP3A4 422/4885CYP2C19 29/4885 |
| US-20230277566-A1 | BROAD SPECTRUM ANTIVIRAL AND METHODS OF USE | MAVS, EIF2AK2, ZC3HAV1 | CYP2C9 1952/4885CYP3A4 1008/4885CYP2C19 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.